Topic: antibiotic-resistant bacteria
Blueberry Therapeutics raised £10 million in series B funding that will advance a nanomedicine for athlete's foot and a fungal nail infection.
An FDA advisory committee voted in favor of Paratek’s new antibiotic for acute bacterial skin infections and community-acquired bacterial pneumonia.
The impact of Achaogen’s narrower-than-expected label for Zemdri is now apparent: The biotech has cut 28% of its staff and all but two R&D programs.
One of the founding scientists of Illumina has come out with a new gene-sequencing software startup that aims to tackle antimicrobial resistance.
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.
Spero Therapeutics’s lead candidate will be the subject of a federal interagency collaboration to test the drug against biological threats.
Novartis is the latest big pharma player to decide that developing new anti-infectives isn’t on its priority list.
Scientists are adding antigenic epitopes to an old class of antibiotic to trigger an immune response against Gram-negative bacteria.
A protein called called TWIK2 could pave the way for the development of drugs that tamp down massive inflammatory responses.
A Tufts team has published research that explains how A. baumannii builds a protective coating, allowing it to evade destruction from antibiotics.